CardioACC

CardioACC (Shenzhen Xinhuan Technology Co., Ltd.) is an early commercial-stage medical device company specializing in the development of advanced cardiovascular interventional imaging and treatment technologies. Founded in 2021 and based in Shenzhen, China, the company focuses on high-end active cardiovascular and natural cavity interventional imaging, particularly intracardiac echocardiography (ICE) catheter systems. CardioACC's flagship product, a self-developed 7.5F 2D Single-Use Intracardiac Echocardiography Catheter, received China's National Medical Products Administration (NMPA) Class III approval in 2025. The company is also developing a 4D ICE system that integrates multiple ultrasound imaging technologies like soft beam synthesis and arbitrary waveform emission. In 2026, Medtronic made a strategic investment in CardioACC to integrate its ICE technology into Medtronic's electrophysiology ecosystem.